Adenosine - Cyclic AMP pathways and cytokine expression

European Cytokine Network

Volumn 10, Issue 3, 1999, Pages 319-328

  Zidek, Zdenek ^a  

^a INSTITUTE OF MATHEMATICS   (Czech Republic)

Author keywords

Adenosine; Cyclic AMP; Cytokines; Interleukin 10; Tumor necrosis factor

Indexed keywords

ADENOSINE RECEPTOR STIMULATING AGENT; ANTIINFLAMMATORY AGENT; CYCLIC AMP; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

CONTROLLED STUDY; CYTOKINE PRODUCTION; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOREGULATION; REVIEW;

ADENOSINE; ANIMALS; CYCLIC AMP; CYTOKINES; FEEDBACK; HUMANS;

EID: 0032829087     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (156)

1. Stone T W, Collis M G, Williams M, Miller I. P, Karasawa A, Hillaire-Buys D. 1995. Adenosine: some therapeutic applications and prospects. In: Pharmacological Sciences: Perspectives for Research and Therapy in the Late 1990s (ed. A C Cuello, B Collier). p. 303. Birkhäuser Verlag, Basel.
2. Poulsen S A, Quinn R J. 1998. Adenosine receptors: new opportunities for future drugs. (Review) Bioorg. Med. Chem. 6: 619.
3. Haskó G, Szabó C, Németh Z H, Kvetan V, Pastores S M, Vizi E S. 1996. Adenosine receptor agonists differentially regulate IL-10, TNF-α, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J. Immunol. 157: 4634.
4. Bardenheuer H, Forst H, Haller M, Peter K. 1990. Influence of improved tissue oxygenation on plasma adenosine (ADO) in septic patients. Int. Care Med. 165: 536.
5. Meno J R, Ngai A C, Ibayashi S, Winn H R. 1991. Adenosine release and changes in pial arteriolar diameter during transient cerebral ischemia and reperfusion. J. Cereb. Blood Flow Metab. 11: 986.
6. Vizi E S, Sperlágh B, Baranyi M. 1992. Evidence that ATP, released from the postsynaptic site by noradrenaline, is involved in mechanical responses of guinea-pig vas deferens: cascade transmission. Neuroscience 50: 455.
7. 2-purinergic receptors for extracellular ATP and other nucleotides. (Review) Am. J. Physiol. 265: C577.
8. 1-adrenoceptors and protein kinase C-mediated activation of ecto-5′-nucleotidase in rat hearts in vivo. J. Physiol. 503: 119.
9. Sperlágh B, Vizi E S. 1996. Neuronal synthesis, storage and release of ATP. Semin. Neurosci. 8: 175.
10. Kirley T L. 1997. Complementary DNA cloning and sequencing of the chicken muscle ecto-ATPase. Homology with the lymphoid cell activation antigen CD39. J. Biol. Chem. 272: 1076.
11. Huu P, Bendahou M, Sourbier P, Hakim J. 1990. Adenosine as a modulator of the inflammatory process, Int. J. Immunotherapy 6: 19.
12. Ontyd J, Schrader J. 1984. Measurement of adenosine, inosine, and hypoxanthine in human plasma. J. Chromatogr. 307: 404.
13. Moser G H, Schrader J, Deussen A. 1989. Turnover of adenosine in plasma of human and dog blood. Am. J. Physiol 256: C799.
14. Barnes C R, Mandell G L, Carper H T, Luong S, Sullivan G W. 1995. Adenosine modulation of tumor necrosis factor-α-induced neutrophil activation. Biochem. Pharmacol. 50: 1851.
15. Delabar U, Kloor D, Luippold G, Mühlbauer B. 1999. Simulateneous determination of adenosine, S-adenosylhomocysteine and S-adenosylmethionine in biological samples using solid-phase extraction and high-performance liquid chromatography. J. Chromatogr. B 724: 231.
16. Fedyk E R, Adawi A, Looney R J, Phipps R P. 1996. Regulation of IgE and cytokine production by cAMP: Implications for extrinsic asthma. (Review) Clin. Immunol. Immunopathol. 81: 101.
17. Khan M M, Sansoni P, Engleman E G, Melmon K L. 1985. Pharmacologic effects of autocoids on subsets of T cells. Regulation of expression/function of histamine-2 receptors by a subset of suppressor cells. J. Clin. Invest. 75: 1578.
18. Burchiel S W, Hanson K, Warner N L. 1984. Clonal heterogenity of cyclic AMP responsivennes: A comparison of malignant murine lymphoid cell lines. Int. J. Immunopharmac. 6: 35.
19. Hill S J. 1992. Multiple histamine receptors: properties and functional characteristics. (Review) Biochem. Soc. Trans. 20: 122.
20. Bonney R J, Burger S, Davies P, Kuehl F A, Humes J L. 1980. Prostaglandin E2 and prostacyclin elevate cyclic AMP levels in elicited populations of mouse peritoneal macrophages. Adv. Prostaglandin Leukotriene Thromboxane Res. 8: 1681.
21. Paietta E, Schwarzmeier J D. 1983. Differences in beta-adrenergic receptor density and adenylate cyclase activity between normal and leukaemic leukocytes. Eur. J. Clin. Invest. 13: 339.
22. Phipps R P, Stein S H, Roper R L. 1991. A new view of prostaglandin E regulation of the immune response. (Review) Immunol. Today 12: 349.
23. Roper R L, Phipps R P. 1992. Prostaglandin E2 and cAMP inhibit B lymphocyte activation and simultaneously promote IgE and IgGl synthesis. J. Immunol. 149: 2984.
24. Lim L K, Hunt N H, Eichner R D, Weidemann M J. 1983. Cyclic AMP and the regulation of prostaglandin production by macrophages. Biochem. Biophys. Res. Commun. 114: 248.
25. Boraschi D, Censini S, Bartalini M, Scapigliati G, Barbarulli G, Vicenzi E, Donati M B, Taglibaue A. 1984. Interferon inhibits prostaglandin biosynthesis in macrophages: effects on arachidonic acid metabolism. J. Immunol. 132: 1987.
26. Fiebich B L, Biber K, Lieb K, van Calker D, Berger M, Bauer J, Gebicke-Haerter P J. 1996. Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors. Glia 18: 152.
27. Bonhaus D W, Chang L K, Kwan J, Martin G R. 1998. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J. Pharm. Exp. Ther.: 287: 884.
28. Hofmann B, Nishanian P, Nguyen T, Insixiengmay P, Fahey J L. 1993. Human immunodeficiency virus proteins induce the inhibitory cAMP/protein kinase A pathway in normal lymphocytes. Proc. Natl Acad. Sci. USA 90: 6676.
29. Haraguchi S, Good R A, Day N K. 1995. Immunosuppressive retroviral peptides: cAMP and cytokine patterns. (Review) Immunol. Today 16: 595.
30. Nokta M, Pollard R. 1991. Human immunodeficiency virus infection: association with altered intracellular levels of cAMP and cGMP in MT-4 cells, Virology 181: 211.
31. Hofmann B, Nishanian P, Nguyen T, Liu M, Fahey J L. 1993. Restoration of T-cell function in HIV infection by reduction of intracellular cAMP levels with adenosine analogues. AIDS 7: 659.
32. Chowdhury M I, Koyanagi Y, Horiuchi S, Hazeki O, Ui M, Kitano K, Golde D W, Takada K, Yamamoto N. 1993. cAMP stimulates immunodeficiency vires (HIV-1) from latently infected cells of monocyte-macrophage lineage: synergism with TNF-alpha. Virology 194: 345.
33. Angel J B, Saget B M, Welsh S P, Greten T F, Dinarello C A, Skolnik P R, Endres S. 1995. Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication. AIDS 9: 1137.
34. Beavo J A. 1995. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. (Review) Physiol. Rev. 75: 725.
35. Rybalkin S D, Beavo J A. 1996. Multiplicity within cyclic nucleotide phosphodiesterases. (Review) Biochem. Soc. Trans. 24: 1005.
36. Beavo J A, Reifsnyder D H. 1990. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. (Review) Trends Pharmacol. Sci. 11: 150.
37. Müller T, Engels P, Fozard J R. 1996. Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. (Review) Trendy Pharmacol. Sci. 17: 294.
38. Haskó G, Szabó C, Németh Z H, Salzman A L, Vizi E S. 1998. Suppression of IL-12 production by phosphodiesterase inhibition in murine endotoxemia is IL-10 independent. Eur. J. Immunol. 28: 468.
39. Torphy T J, Undem B J. 1991. Phosphodiesterase inhibitors: new oportunities for the treatment of asthma. (Review) Thorax 46: 512.
40. Fredholm B B, Abbracchio M P, Burnstock G, Daly J W, Harden T K, Jacobsen K A, Leff P, Williams M. 1994. Nomenclature and classification of purinoceptors. (Review) Pharmacol. Rev. 46: 143.
41. Olah M E, Stiles G L. 1995. Adenosine receptor subtypes: characterization and therapeutic regulation. (Review) Annu. Rev. Pharmacol. Toxicol. 35: 581.
42. Palmer T M, Gettys T W, Stiles G L. 1995. Differential interaction with and regulation of multiple G-proteins by the rat A3 adenosine receptor. J. Biol. Chem. 270: 16895.
43. Strickler J, Jacobsen K A, Liang B T. 1996. Direct preconditioning of cultured chick ventricular myocytes. Novel functions of cardiac adenosine A2a and A3 receptors. J. Clin. Invest. 98: 1773.
44. Barnard E A, Burnstock G, Webb T E. 1994. G protein-coupled receptors for ATP and other nucleotides: a new receptor family. (Review) Trends Pharmacol. Sci. 15: 67.
45. Satchell D. 1984. Purine receptors: classification and properties. (Review) Trends Pharmacol. Sci. 5: 340.
46. Dalziel H H. Westfall D P. 1994. Receptors for adenine nucleotides and nucleosides: subclassification, distribution, and molecular characterization. (Review) Pharmacol. Rev. 46: 449.
47. Palmer T M, Stiles G L. 1995. Adenosine receptors. (Review) Neuopharmacol. 34: 683.
48. Eppel B A, Newell A M, Brown E J. 1989. Adenosine receptors are expressed during differentiation of monocytes to macrophages in vitro. J. Immunol. 143: 4141.
49. Salmon J E, Brogle N. Brownlie C, Edberg J C. Kimberly R P, Chen B X, Erlanger B E 1993. Human mononuclear phagocytes express adenosine A, receptors. A novel mechanism for differential regulation of the gamma receptor function. J. Immunol. 151: 2775.
50. 3 receptor. Drug Dev. Res. 37: 145.
51. 3 adenosine receptors on human eosinophils elevates intracellular calcium. Blood 88: 3569.
52. 3 receptors in mast cells. Trends Pharmacol. Sci. 15: 13.
53. Ali H, Cunha-Melo J R, Saul W F, Beaven M A. 1990. Activation of phospholipase C via adenosine receptors provides synergistic signals for secretion in antigen stimulated RBL-2H3 cells. Evidence for a novel adenosine receptor, J. Biol. Chem. 265: 745.
54. 3 receptor. Proc. Natl. Acad. Sci. USA 89: 7432.
55. 3 receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J. Biol. Chem. 268: 16887.
56. McWhinney C D, Dudley M W, Bowlin T L, Peet N P, Schook L, Bradshaw M, De M, Borcherding D R, Edwards C K 3rd. 1996. Activation of adenosine A receptors on macrophages inhibits tumor necrosis factor-α. Eur. J. Pharmacol. 310: 209.
57. Gonzalez G A, Montminy M R, 1989. Cyclic AMP stimulates stomatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 59: 675.
58. Sassone-Corsi P. 1998. Coupling gene expression to cAMP signalling: role of CREB and CREM. (Review) Int. J. Biochem. Cell Biol. 30: 27.
59. Englaro W, Rezzonico R, Durand-Clement M, Lallemand D, Ortonne JP, Balotti R. 1995. Mitogen-activated protein kinase pathway and AP-1 are activated during cAMP-induced melanogenesis in B-16 melanoma cells. J. Biol. Chem. 270: 24315.
60. Park K, Kim K H. 1993. The site of cAMP action in the insulin induction of gene expression of acetyl-CoA carboxylase is AP-2. J. Biol. Chem. 268: 17811.
61. Venepally P, Waterman M R. 1995. Two Spl-binding sites mediate cAMP-induced transcription of the bovine CYP11A gene through the protein kinase A signaling pathway. J. Biol. Chem. 270: 25402.
62. Okimura Y, Howard P W, Maurer R A. 1994. Pit-1 binding sites mediate transcriptional responses to cyclic adenosine 3′,5′-monophosphate through a mechanism that does not require inducible phosphorylation of Pit-1. Mol. Endocrinol. 8: 1559.
63. Rangan V S, Oskouian B, Smith S. 1996. Identification of an inverted CCAAT box motif in the fatty-acid synthase gene as an essential element for modification of transcriptional regulation by cAMP. J. Biol. Chem. 271: 2307.
64. Aronica S M, Katzenellenbogen B S. 1989. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol. Endocrinol. 7: 743.
65. Metz R, Ziff E. 1991. cAMP stimulates the C/EBP-related transcription factor rNFIL-6 to translocate to the nucleus and induce c-fos transcription. Genes Dev. 5: 1754.
66. Roesler W J, Graham J G, Kolen R, Klemm D J, McFie P J. 1995. The cAMP response element binding protein synergizes with other transcription factors to mediate cAMP responsiveness. J. Biol. Chem. 270: 8225.
67. Jiang H, Colbran J L, Francis S H, Corbin J D. 1992. Direct evidence for cross-activation of cGMP-dependent protein kinase by cAMP in pig coronary arteries. J. Biol. Chem. 267: 1015.
68. Kessler T, Lugnier C. 1995. Rolipram increases cyclic GMP content in L-arginine-treated cultured bovine aortic endothelial cells. Eur. J. Pharmacol. 290: 163.
69. Ignarro L J. 1991. Heme-dependent activation of guanylate cyclase by nitric oxide: a novel signal transduction mechanism. (Review) Blood Vessels 28: 67.
70. Bomsztyk K, Toivola B, Emery D W, Rooney J W, Dower S K, Rachie N A, Sibley C H. 1990. Role of cAMP in interleukin-1-induced kappa light chain gene expression in murine B cell line. J. Biol. Chem. 265: 9413.
71. Chen D, Rothenberg E V. 1994. Interleukin-2 transcription factors as molecular targets of cAMP inhibition: delayed inhibition kinetics and combinatorial transcription roles. J. Exp. Med. 179: 931.
72. de Murcia G, Menissier de Murcia J. 1994. Poly (ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem. Sci. 19: 172.
73. Shall S. 1995. ADP-ribosylation reactions. (Review) Biochimie 77: 313.
74. Hausehildt S, Scheipers P, Bessler W G. 1991. Inhibitors of poly (ADP-ribose) polymerase suppress lipopolysaccharide-induced nitrite formation in macrophages. Biochem. Biophys. Res. Commun. 179: 865.
75. Pellat-Deceunynek C, Wietzerbin J, Drapier J C. 1994. Nicotinamide inhibits nitrie oxide synthase mRNA induction in activated macrophages. Biochem. J. 297: 53.
76. Heine H, Ulmer A J, Flad H D, Hausehildt S. 1995. Lipopolysaccharide-induced change of phosphorylation of two cytosolic proteins in human monocytes is prevented by inhibitors or ADP-ribosylation. J. Immunol. 155: 4899.
77. Le Page C, Saneeau J, Drapier J C, Wietzerbin J. 1998. Inhibitors of ADP-ribosylation impair inducible nitric oxide synthase gene transcription through inhibition of NF kappa B activation. Biochem. Biophys. Res. Common. 243: 451.
78. 2 receptors on rat Kupffer cells. Hepatology 19: 1445.
79. Le Moine O, Stordeur P, Schandané L, Marchant A, de Groote D, Goldman M, Deviere J. 1996. Adenosine enhances IL-10 secretion by human monocytes. J. Immunol. 156: 4408.
80. Bouma M G, Stad R K, van den Wildenberg F A, Buurman W A. 1994. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J. Immunol 153: 4159.
81. Sajjadi F G. Tabayashi K, Foster A C, Domingo R C, Firestein G S. 1996. Inhibition of TNF-α expression by adenosine: rotc of A3 adenosine receptors. J. Immunol. 156: 3435.
82. Le Vraux V, Chen Y L, Masson I, De Sousa M, Giroud J P, Florentin I, Chauvelot-Moachon L. 1993. Inhibition of human monocyte TNF production by adenosine receptor agonists. Life Sci. 52: 1917.
83. Eigler A, Greten T F, Sinha B, Haslberger C, Sullivan G W, Endres S. 1997. Endogenous adenosine curtails lipopolysaccha-ride-stimulated tumour necrosis factor synthesis. Scand. J. Immunol. 45: 132.
84. Proctor R A, Denlinger L C, Leventhal P S, Daugherty S K, van de Loo J W, Tanke T, Firestein G S, Bertics P J. 1994. Protection of mice from endotoxic death by 2-methylthio-ATP. Proc. Natl. Acad. Sci. USA 91: 6017.
85. Klemm P, Harris H J, Perretti M. 1995. Effect of rolipram in a murine model of acute inflammation: comparisin with the corticoid dexamethasone. Eur. J. Pharmacol. 281: 69.
86. Prabhakar U, Lipshutz D, Bartus J O, Slivjak M J, Smith E F, 3rd Lee J C, Esser K M. 1994. Characterization of cAMP-dependent inhibition of LPS-induced TNF-α production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int. J. Immunopharmac. 16: 805.
87. Tannenbaum C S, Hamilton T A. 1989. Lipopolysaccharide-induced gene expression in marine peritoneal macrophages is selectively suppressed by agents that elevate intracellular cAMP. J. Immunol. 142: 1274.
88. 2 regulates macrophage-derived tumor necrosis factor gene expression. J. Biol. Chem. 263: 5380.
89. Endres S, Fülle H J, Sinha B, Stoll D, Dinarello C A, Gerzer R, Weber P C. 1991. Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-α and interleukin-1β by human mononuclear cells. Immunology 72: 56.
90. Spengler R N, Chensue S W, Giacherio D A, Blenk N, Kunkel S L. 1994. Endogenous norepinephrine regulates tumor necrosis factor-α production from macrophages in vitro. J. Immunol. 152: 3024.
91. Seldon P M, Barnes P J, Meja K, Giembyez M A. 1995. Suppression of lipopolysaccharid-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Mol. Pharmacol. 48: 747.
92. Sekut L, Champion B R, Page K, Menius J A Jr. Connolly K M. 1995. Anti-inflammatory activity of salmeterol: down-regulation of cytokine production. Clin. Exp. Immunol. 99: 461.
93. Strieter R M, Remiek D G, Ward P A, Spengler R N, Lynch J P 3rd, Larrick J, Kunkel S L. 1988. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem. Biophys. Res. Commun. 155: 1230.
94. Bailly S, Ferrua B, Fay M, Gougerot-Pocidalo M A. 1990. Differential regulation of IL-6, IL-1A, IL-1beta and TNF-alpha production in LPS-stimulated human monocytes: role of cyclic AMP. Cytokine 2: 205.
95. Arai T, Hiromatsu K, Kobayashi N, Takano M, Ishida H, Nimura Y, Yoshikai Y. 1995. IL-10 is involved in the protective effect of dibutyryl cyclic adenosine monophosphate on endotoxin-induced inflammatory liver injury. J. Immunol. 155: 5743.
96. Greten T F, Eigler A, Sinha B, Moeller J, Endres S. 1995. The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-α and nitric oxide. Int. J. Immunopharmacol. 17: 605.
97. Kambayashi T, Jacob C O, Zhou D, Mazurek M, Fong M, Strassmann G. 1995. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-α and IL-6 release by endotoxin-stimulated macrophages. J. Immunol. 155: 4909.
98. Sinha B, Semmler J, Eisenhut T, Eigler A, Endres S. 1996. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur. J. Immunol. 25: 147.
99. Semmler J, Wachtel H, Endres S. 1993. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells, Int. J. Immunopharmacol. 15: 409.
100. Badger A M, Olivera D L, Esser K M. 1994. Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxyfilline, and rolipram in a murine model of endotoxin shock. Circ. Shock 44: 188.
101. Eigler A, Siegmund B, Emmerich U, Baumann K H, Hartmann G, Endres S. 1998. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J. Leukoc. Biol. 63: 101.
102. 3 receptors decreases interleukin-12 and interferon-γ production and prevents lethality in endotoxemic mice. Eur. J. Pharmacol. 358: 261.
103. Nyman U, Mussener A, Larsson E, Lorentzen J, Klareskog L. 1997. Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram. Clin. Exp. Immunol. 108: 415.
104. Sommer N, Loschmann P A, Northoff G H, Weller M, Steinbrecher A, Steinbach J P, Lichtenfels R, Meyrmann R, Reithmuller A, Fontana A, Dichgans J, Martin R. 1995. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat. Med. 1: 244.
105. + T cell clone. Cell. Immunol. 172: 200.
106. Szabó C, Scott G S, Virág L, Egnaczyk G, Salzman A L, Shanley T P, Hasko G. 1998. Suppression of macrophage inflammatory protein (MIP)-1α. production and collagen-induced arthritis by adenosine receptor agonists. Br. J. Pharmacol. 125: 379.
107. Shanley T P, Haskó G, Egnaczyk G, Salzman A L, Szabó C. 1998. Suppression of macrophage inflammatory protein (MIP))-I alpha production by adenosine receptor agonists in immunostimulated macrophages. FASEB J 12: A766.
108. Martin C A, Dorf M E. 1991. Differential regulation of interleukin-6, macrophage inflammatory protein-1, and JE/MCP-1 cytokine expression in macrophage cell lines. Cell Immunol. 135: 245.
109. Semmler J, Gebert U, Eisenhut T, Moeller J, Schonharting M M, Allera A, Endres S. 1993. Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity. Immunology 78: 520.
110. Lorenz J J, Furdon P J, Taylor J D, Verghese M W, Chandra G, Kost T A, Haneline S A, Roner L A, Gray J G. 1995. A cyclic adenosine 3, 5 -monophosphate signal is required for the induction of IL-1 beta by TNF-alpha in human monocytes. J. Immunol. 155: 836.
111. Takii T, Akahoshi T, Kato K, Hayashi H, Marunouchi T, Onozaki K. 1992. Interleukin-1 up-regulates transcription of its own receptor in a human fibroblast cell line TIG-I: role of endogenous PGE2 and cAMP. Eur. J. Immunol. 22: 1221.
112. Mary D, Aussel C, Ferrua B, Fehlmann M. 1987. Regulation of interleukin 2 synthesis by cAMP in human T cells. J. Immunol. 139: 1179.
113. Paliogianni F, Kincaid R L, Boumpas D T. 1993. Prostaglandin E2 and other cyclic AMP elevating agents inhibit interleukin-2 gene transcription by counteracting calcineurin-dependent pathways. J. Exp. Med. 178: 1813.
114. Novogrodsky A, Patya M, Rubin A L, Stenzel K H. 1983. Agents that increase cellular cAMP inhibit production of interleukin-2, but not its activity. Biochem. Biophys. Res. Commun. 114: 93.
115. Rincon M, Tugores A, Lopez-Rivas A, Silva A, Alonso M, De Landazuri M O, Lopez-Botet M. 1988. Prostaglandin E2 and the increase of intracellular cAMP inhibit the expression of interleukin-2 receptors in human T cells. Eur. J. Immunol. 18: 1791.
116. Borger P, Kauffman H F, Vijgen J L, Postma D S, Vellenga E. 1996. Activation of the cAMP-dependent signaling pathway downregulates the expression of interleukin-3 and granulocyte-macrophage colony-stimulating factor in activated human T lymphocytes. Exp. Hematol. 24: 108.
117. Borger P, Kauffman H F, Postma D S, Vellenga E. 1996. Interleukin-4 gene expression in activated human T lymphocytes is regulated by the cyclic adenosine monophosphate-dependent signaling pathway. Blood 87: 691.
118. Novak T J, Rothenberg E V. 1990. cAMP inhibits induction of interleukin-2 but not of interleukin-4 in T cells. Proc. Natl. Acad. Sci. USA 87: 9353.
119. Siegel M D, Zhang D H, Ray P, Ray A. 1995. Activation of the interleukin-5 promoter by cAMP in murine EL-4 cells requires the GATA-3 and CLE0 elements. J. Biol. Chem. 270: 24548.
120. Fiebich B L, Biber K, Gyufko K, Berger M, Bauer J, van Calker D. 1996. Adenosine A2b receptors mediate an increase in interleukin-(IL)-6 mRNA and IL-6 protein synthesis in human astroglioma cells. J. Neurochem. 66: 1426.
121. Spangelo B L, Judd A M, MacLeod R M, Goodman D W, Isakson P C. 1990. Endotoxin-induced release of interleukin-6 from rat medial basal hypothalami. Endocrinology 127: 1779.
122. Spangelo B L, Isakson P C, MacLeod R M. 1990. Production of interleukin-6 by anterior pituitary cells is stimulated by increased intracellular adenosine 3′,5′-monophosphate and vasoactive intestinal peptide. Endocrinology 127: 403.
123. Huttner A, Lei T, Fahlbusch R, Schrell W, Adams E E 1996. Relationship between cAMP induced inhibition of human meningioma cell proliferation and autocrine secretion of interleukin-6. Life Sci. 58: 1323.
124. Robson R L, Westwick J, Brown Z. 1995. Interleukin-1-induced IL-8 and IL-6 gene expression and production in human mesangial cells is differentially regulated by cAMP. Kidney Int. 48: 1767.
125. Greenfield E M, Horowitz M C, Lavish S A. 1996. Stimulation by parathyroid hormone of interleukin-6 and leukemia inhibitory factor expression in osteoblasts is an immediate-early gene response induced by cAMP signal transduction. J. Biol. Chem. 271: 10984.
126. Zitnik R J, Zheng T, Elias J P. 1993. cAMP inhibition of interleukin-1-induced interleukin-6 production by human lung fibroblasts. Am. J. Physiol. 264: L253.
127. Turner C R, Esser K M, Wheeldon E B. 1993. Therapeutic intervention in a rat model of ARDS: IV. Phosphodiesterase IV inhibition. Circ. Shock 39: 237.
128. Platzer C, Meisel C, Vogt K, Platzer M, Volk H D. 1995. Up-regulation of monocytic IL-10 by tumor necrosis factor-α and cAMP elevating drugs. Int. Immunol. 7: 517.
129. Suberville S, Bellocq A, Fouqueray B, Philippe C, Lantz O, Perez J, Baud L. 1996. Regulation of interleukin-10 production by β-adrenergic agonists. Eur. J. Immunol. 26: 2601.
130. Wang P, Tait S M, Ba Z F, Chaudry I H. 1995. Tumor necrosis factor-α administration increases Kupffer cell cyclic adenosine monophosphate levels. Shock 4: 351.
131. Galea P, Thibuult G, Lacord M, Bardos P, Lebranchu Y. 1993. IL-4, but not tumor necrosis factor-alpha, increases endothelial cell adhesiveness for lymphocytes by activating a cAMP-dependent pathway, J. Immunol. 151: 588.
132. Zhang Y H, Lin J X, Yip Y K, Vilcek J. 1988. Enhancement of cAMP levels and of protein kinase activity by tumor necrosis factor and interleukin-1 in human fibroblasts: role in the induction of interleukin-6. Proc. Natl. Acad. Sci. USA 85: 6802.
133. Nolte A, Bechtner G, Rafferzeder M, Gartner R. 1994. Interleukin- beta (IL-1 beta) binds to intact porcine thyroid follicles, decreases iodide uptake but has no effect on cAMP formation or proliferation. Horm. Metab. Res. 26: 413.
134. Ray K, Thompson N, Kennard N, Rollins P, Grenfell S, Witham S, Smithers N, Solari R. 1992. Investigation of guanine-nucleotide-binding protein involvement and regulation of cyclic AMP metabolism in interleukin-1 signal transduction. Biochem. J. 282: 59.
135. Renkonen R, Mattila P, Hayry P, Ustinov J. 1990. Interleukin 1-induced lymphocyte binding to endothelial cells. Role of cAMP as a second messenger, Eur. J. Immunol. 20: 1563.
136. Lehmmann V, Benninghoff B, Droge W. 1988. Tumor necrosis factor-induced activation of peritoneal macrophages is regulated by prostaglandin E2 and cAMP. J. Immunol. 141: 587.
137. Anderson G D, Hauser S D, McGarity K L, Bremer M E, Isakson P C, Gregory S A. 1996. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin-6 in rat adjuvant arthritis. J. Clin. Invest. 97: 2672.
138. 4 and other eicosanoids by macrophages. Lymphokine Res. 8: 107.
139. Atkinson Y H, Murray A W, Krilis S, Vadas M A, Lopez A F. 1990. Human tumour necrosis factor-alpha (TNF-α) directly stimulates arachidonic acid release in human neutrophils, Immunology 70: 82.
140. Bona C A, Siminovitch K A, Zanetti M, Theofilopoulos A N. 1993. The Molecular Pathology of Autoimmune Diseases. Harwood Academic Publishers GmbH, Chur.
141. Michie H R. 1998. The value of animal models in the development of new drugs for the treatment of the sepsid syndrome. (Review) J. Antimicrob. Chemother: 41 (Suppl A): 47.
142. Karima R, Matsumoto S, Higashi H, Matsushima K. 1999. The molecular pathogenesis of endotoxic shock and organ failure. Mol. Med. Today 5: 123.
143. Bergman M R, Holycross B J. 1996. Pharmacological modulation of myocardial tumor necrosis factor a production by phosphodiesterase inhibitors. J. Pharmacol. Exp. Ther. 279: 247.
144. Ma D, Wu P, Egan R W, Billah M M, Wang P. 1999. Phosphodiesterase 4B gene transcription is activated by lipopolysaccharide and inhibited by interleukin-10 in human monocytes. Mol. Pharmacol. 55: 50.
145. Moochhala S M, Hon W M, Chhatwal V J, Khoo H E. 1996. Expression of inducible nitric oxide synthase in mice: pharmacological evaluation of adenosine receptor agonists. Eur. J. Pharmacol. 316: 287.
146. Ikeda U, Kurosaki K, Ohya K, Shimada K. 1997. Adenosine stimulates nitric oxide synthesis in vascular smooth muscle cells. Cardiovase. Res. 35: 168.
147. 1 adenosine receptors modulate respiratory activity of the neonatal mouse via the cAMP-mediated signaling pathway. J. Neurophysiol. 81: 247.
148. Mosmann T R, Coffman R L. 1989. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. (Review) Anna. Rev Immunol. 7: 145.
149. Romagnani S. 1994. Lymphokine production by human T cells in disease states. (Review) Annu. Rev. Immunol. 12: 227.
150. de Waal Malefyt R, Moore K W. 1998. Interleukin-10. In: The Cytokine Handbook (ed. A W Thomson), 3rd edn, p. 333. Academic Press, San Diego.
151. de Vries J E. 1995. Immunosuppressive and anti-inflammatory properties of interleukin-10. (Review) Ann. Med. 27: 537.
152. Seldon P M. Barnes P J, Giembycz M A. 1996. The inhibitory effect of cyclic AMP-elevating drugs on LPS-induced TNF-α generation from human monocytes is not mediated by IL-10 (abstract). Br. J. Pharmacol. 119: 159.
153. Genain C P, Roberts T, Davis R L, Nguyen M H, Uccelli A, Faulds D, Li Y, Hedgpeth J, Hauser S L. 1995. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc. Natl. Acad. Sci. USA 92: 3601.
154. Cronstein B N. 1995. A novel approach to the development of anti-inflammatory agents: adenosine release at inflamed sites. (Review) J. Invest. Med. 43: 50.
155. Gadangi P, Longaker M, Naime D, Levin R I, Recht P A, Montesinos M C, Buckley M T, Carlin G, Cronstein B N. 1996. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J. Immunol. 156: 1937.
156. 2A adenosine receptors in inflammation. Drug Dev. Res. 45: 103.